Who are ASC40 tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ASC40.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/asc40-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

ASC40 tablets — Competitive Intelligence Brief

ASC40 tablets (ASC40 tablets) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HBV capsid assembly inhibitor. Area: Virology / Hepatology.

phase 3 HBV capsid assembly inhibitor HBV core antigen (capsid assembly) Virology / Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

ASC40 tablets (ASC40 tablets) — Ascletis Pharmaceuticals Co., Ltd.. ASC40 is a hepatitis B virus (HBV) capsid assembly modulator that disrupts viral particle formation.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ASC40 tablets TARGET	ASC40 tablets	Ascletis Pharmaceuticals Co., Ltd.	phase 3	HBV capsid assembly inhibitor	HBV core antigen (capsid assembly)
ASC40	ASC40	Ascletis Pharmaceuticals Co., Ltd.	phase 3	HBV capsid assembly inhibitor	HBV core antigen (HBcAg)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HBV capsid assembly inhibitor class)

Ascletis Pharmaceuticals Co., Ltd. · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ASC40 tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/asc40-tablets. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab